Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations

References

• JuliussonGHoughRLeukemiaProg Tumor Res2016438710027595359
   PubMed Web of Science ®Google Scholar
• PuiCHCarrollWLMeshinchiSArceciRJBiology, risk stratification, and therapy of pediatric acute leukemias: an updateJ Clin Oncol201129555156521220611
   PubMed Web of Science ®Google Scholar
• JabbourEJEsteyEKantarjianHMAdult acute myeloid leukemiaMayo Clin Proc200681224726016471082
   PubMed Web of Science ®Google Scholar
• LöwenbergBOssenkoppeleGJvan PuttenWHigh-dose daunorubicin in older patients with acute myeloid leukemiaN Engl J Med2009361131235124819776405
   PubMed Web of Science ®Google Scholar
• ParkHYoukJKimIComparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemiaAnn Hematol201695111777178627539617
   PubMed Web of Science ®Google Scholar
• HuhmannIMWatzkeHHGeisslerKFLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemiaAnn Hematol19967362652719003155
   PubMed Web of Science ®Google Scholar
• ChristmanJK5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapyOncogene200221355483549512154409
   PubMed Web of Science ®Google Scholar
• RitchieEKFeldmanEJChristosPJDecitabine in patients with newly diagnosed and relapsed acute myeloid leukemiaLeuk Lymphoma20135492003200723270581
   PubMed Web of Science ®Google Scholar
• KantarjianHIssaJPRosenfeldCSDecitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyCancer200610681794180316532500
   PubMed Web of Science ®Google Scholar
• BallBZeidanAGoreSDPrebetTHypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomingsLeuk Lymphoma20175851022103627654579
   PubMed Web of Science ®Google Scholar
• DuongVHKomrokjiRSListAFUpdate on the pharmacotherapy for myelodysplastic syndromesExpert Opin Pharmacother201415131811182525080144
   PubMed Web of Science ®Google Scholar
• KantarjianHMThomasXGDmoszynskaAMulticenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemiaJ Clin Oncol201230212670267722689805
   PubMed Web of Science ®Google Scholar
• MalikPCashenAFDecitabine in the treatment of acute myeloid leukemia in elderly patientsCancer Manag Res20146536124520204
   PubMed Web of Science ®Google Scholar
• KrögerNStübigTAtanackovicDImmune-modulating drugs and hypomethylating agents to prevent or treat relapse after allogeneic stem cell transplantationBiol Blood Marrow Transplant201420216817224067503
   PubMed Web of Science ®Google Scholar
• SongLXXuLLiXClinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemiaAnn Hematol201291121879188622895556
   PubMed Web of Science ®Google Scholar
• LiJChenYZhuYEfficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemiaOncotarget2015686448645825749041
   PubMedGoogle Scholar
• JinJChinese Society of Hematology, Chinese Medical AssociationChinese guidelines for the diagnosis and treatment of relapsed and refractory acute myelogenous leukemiaZhonghua Xue Ye Xue Za Zhi2011321288788822339973
   PubMedGoogle Scholar
• ZhuHHJiangHJiangBCytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapyLeuk Lymphoma201354112452245723432721
   PubMed Web of Science ®Google Scholar
• ChesonBDBennettJMKopeckyKJRevised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJ Clin Oncol200321244642464914673054
   PubMed Web of Science ®Google Scholar
• EsteyEAcute Myeloid Leukemia – Many Diseases, Many TreatmentsN Engl J Med2016375212094209527959719
   PubMed Web of Science ®Google Scholar
• PhillipsCLDaviesSMMcmastersRLow dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adultsBr J Haematol2013161340641023432727
   PubMed Web of Science ®Google Scholar
• IssaJPGarcia-ManeroGHuangXResults of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemiaCancer2015121455656125336333
   PubMed Web of Science ®Google Scholar
• WuQHeGDepeiWOutcome of dose-adjusted Decitabine regimen compared with FLAG regimen in the treatment of relapsed/refractory acute myeloid leukemiaBlood2013122215031
   Web of Science ®Google Scholar
• UstunCKallaAFarrowSDeremerDLJillellaADecitabine as “bridge therapy” to a MUD transplant in relapsed AML postautologous stem cell transplantationAm J Hematol20088310825827
   Web of Science ®Google Scholar
• GangulySAminMDivineCAljitawiOSAbhyankarSMcguirkJPDecitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)Ann Hematol201392454955023111661
   PubMed Web of Science ®Google Scholar
• LeeSRYangDHAhnJSThe clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemiaJ Korean Med Sci200924349850319543516
   PubMed Web of Science ®Google Scholar
• ChauhanPSIhsanRSinghLCGuptaDKMittalVKapurSMutation of NPM1 and FLT3 genes in acute myeloid leukemia and their association with clinical and immunophenotypic featuresDis Markers201335558158824288427
   PubMed Web of Science ®Google Scholar
• CreutzigUZimmermannMReinhardtDChanges in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groupsCancer2016122243821383027529519
   PubMed Web of Science ®Google Scholar
• HajjiNMateosSPastorNDomínguezICortésFInduction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitorMutat Res20055831263515866463
   PubMed Web of Science ®Google Scholar